Lyra Therapeutics, Inc. (LYRA)
NASDAQ: LYRA · Real-Time Price · USD
0.178
-0.018 (-9.04%)
At close: Nov 20, 2024, 4:00 PM
0.185
+0.007 (3.65%)
Pre-market: Nov 21, 2024, 7:36 AM EST
Lyra Therapeutics Employees
Lyra Therapeutics had 88 employees as of December 31, 2023. The number of employees increased by 30 or 51.72% compared to the previous year.
Employees
88
Change (1Y)
30
Growth (1Y)
51.72%
Revenue / Employee
$16,716
Profits / Employee
-$1,109,227
Market Cap
11.65M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 88 | 30 | 51.72% |
Dec 31, 2022 | 58 | 5 | 9.43% |
Dec 31, 2021 | 53 | 15 | 39.47% |
Dec 31, 2020 | 38 | 0 | - |
Dec 31, 2019 | 38 | - | - |
Related Stocks
Company Name | Employees |
---|---|
China Jo-Jo Drugstores | 1,003 |
Trinity Biotech | 380 |
PAVmed | 107 |
ImmunoPrecise Antibodies | 101 |
Aspira Women's Health | 64 |
AIM ImmunoTech | 28 |
Talphera | 15 |
QT Imaging Holdings | 14 |
LYRA News
- 8 days ago - Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis - GlobeNewsWire
- 7 weeks ago - Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings - GlobeNewsWire
- 3 months ago - Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis - GlobeNewsWire
- 7 months ago - Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 7 months ago - 3 'Buy-Rated' Biotech Stocks Under $10 - Seeking Alpha